8-K: Pulse Biosciences Announces First Quarter 2025 Financial Results and Business Updates

Pulse Biosciences reported its Q1 2025 financial results, highlighting increased costs due to expanding operations and progress in clinical trials for its nsPFA technology.

Summary

• Pulse Biosciences announced its financial results for the first quarter ended March 31, 2025.
• Total GAAP costs and expenses were $18.0 million, an increase of $7.4 million compared to the prior year period.
• This increase was primarily driven by non-cash stock-based compensation and other compensation and administrative expenses.
• Non-GAAP costs and expenses were $12.7 million, an increase of $4.1 million compared to the prior year period.
• GAAP net loss for the quarter was ($16.8) million, compared to ($10.1) million in the same period last year.
• Non-GAAP net loss was ($11.4) million, compared to ($8.1) million in the prior year period.
• Cash and cash equivalents totaled $119.3 million as of March 31, 2025, compared to $34.9 million as of March 31, 2024, and $118.0 million as of December 31, 2024.
• Cash used in operating activities in the first quarter of 2025 totaled $13.5 million, compared to $9.8 million used in the same period in the prior year.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is experiencing increased losses and expenses, it is also making progress in clinical trials and commercialization efforts. The management's comments are optimistic, but the financial results are concerning.

Positives

• The company is expanding commercial resources for the launch of the nsPFA Percutaneous Electrode.
• EU approval was received to expand the clinical protocol for the nsPFA Cardiac Surgery System feasibility study.
• The company is on track to receive approval to commence a pivotal clinical trial in mid-2025 for FDA approval of the nsPFA Cardiac Surgery System as a treatment for AF.
• Clinical data on the catheter-based treatment of AF with the nsPFA 360 catheter were presented, demonstrating excellent procedure efficiency and acute outcomes.
• 100 patients have been treated in Europe with the nsPFA 360 catheter in the first-in-human feasibility study for AF treatment.
• Cash and cash equivalents totaled $119.3 million as of March 31, 2025.

Negatives

• Total GAAP costs and expenses for Q1 2025 were $18.0 million, an increase of $7.4 million year-over-year.
• Non-GAAP costs and expenses for Q1 2025 were $12.7 million, an increase of $4.1 million year-over-year.
• GAAP net loss for Q1 2025 was ($16.8) million, compared to ($10.1) million for Q1 2024.
• Non-GAAP net loss for Q1 2025 was ($11.4) million, compared to ($8.1) million for Q1 2024.
• Cash used in operating activities in the first quarter of 2025 totaled $13.5 million, compared to $9.8 million used in the same period in the prior year.

Risks

• The company's forward-looking statements are subject to risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control.
• Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission.

Future Outlook

Pulse Biosciences anticipates expanding commercial efforts and launching the nsPFA Percutaneous Electrode System in the second half of the year and commencing IDEs for the nsPFA Cardiac Surgery System and nsPFA 360 Cardiac Catheter System both in mid-2025.

Management Comments

• We are pleased to be generating mounting clinical evidence that confirms the tremendous benefits of our nsPFA technology across each of our three devices, said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences.
• I am excited by the progress we have made early in 2025.

Industry Context

Pulse Biosciences is operating in the bioelectric medicine space, focusing on nanosecond pulsed field ablation (nsPFA) technology. The company is targeting the atrial fibrillation (AF) market, which is a significant and growing area of unmet medical need. Competitors in this space include companies developing catheter-based ablation systems and surgical ablation devices.

Comparison to Industry Standards

• Companies like Medtronic, Abbott, and Boston Scientific are major players in the cardiac ablation market.
• These companies have established products for treating atrial fibrillation, including radiofrequency ablation and cryoablation technologies.
• Pulse Biosciences' nsPFA technology represents a novel approach, potentially offering advantages in terms of safety and efficacy compared to existing ablation methods.
• The company's clinical trial results will be crucial in determining its competitive positioning against these established players.

Stakeholder Impact

• Shareholders: The increased losses may negatively impact shareholder value in the short term, but progress in clinical trials could provide long-term benefits.
• Employees: The expanding organization may lead to increased job opportunities.
• Customers: The development of new nsPFA devices could provide improved treatment options for patients with atrial fibrillation and other conditions.

Next Steps

• Expand commercial resources for the launch of the nsPFA Percutaneous Electrode.
• Commence a U.S. clinical trial for the nsPFA Percutaneous Electrode System.
• Advance an IDE and receive approval to commence a pivotal clinical trial for the nsPFA Cardiac Surgery System.
• Commence a U.S. IDE pivotal clinical study for the nsPFA 360 Cardiac Catheter System.

Key Dates

Keywords

nsPFA, Pulse Biosciences, Financial Results, Atrial Fibrillation, Ablation, Clinical Trial, Medical Device